Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R. Klein.
Hyperglicemia and microvascular and macrovascular disease in diabetes.
Diabetes Care, 18 (1995), pp. 258-268
[2.]
The Diabetes Control and Complications Trial Research Group.
The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus.
N Engl J Med, 329 (1993), pp. 977-986
[3.]
Y. Ohkubo, H. Kishikawa, E. Araki, T. Miyata, S. Isami, S. Motoyoshi, et al.
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6 years study.
Diabetes Res Clin Frac, 28 (1995), pp. 103-117
[4.]
United Kingdom Prospective Diabetes Study Group.
Intensive blood-glucose control with sulfonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet, 352 (1998), pp. 837-852
[5.]
United Kingdom Prospective Diabetes Study Group.
Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
Lancet, 352 (1998), pp. 854-864
[6.]
S. Vijan, T.P. Hofer, R.A. Hayward.
Estimated benefits of glycemic control in microvascular complications in type 2 diabetes.
Ann Intern Med, 127 (1997), pp. 195-788
[7.]
UK Prospective Diabetes Study Group.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38).
BMJ, 317 (1998), pp. 703-713
[8.]
American Diabetes Association.
Standards of medical care for patients with diabetes mellitus. Clinical Practice Recommendations.
Diabetes Care, 23 (2000), pp. 32-42
[9.]
Canadian Diabetes Association.
1998 clinical guidelines for the management of diabetes in Canada.
CMAJ, 159 (1998), pp. l-l29
[10.]
European Diabetes Policy Group 1998-1999.
A desktop guide to type 2 diabetes mellitus.
Diabetic Med, 16 (1999), pp. 716-730
[11.]
Grupo de Estudio de la diabetes en Atención Primaria de Salud (GEDAPS).
Guía para el tratamiento de la diabetes tipo 2 en la atención primaria.
3.a ed, Harcourt Brace, (2000),
[12.]
H.E. Lebovitz.
Therapy for diabetes mellitus and related disorders.
3.a ed, American Diabetes Association, (1998),
[13.]
R.A. De Fronzo.
Pharmacologic therapy for type 2 diabetes mellitus.
Ann Intern Med, 131 (1999), pp. 281-303
[14.]
S. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakson.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med, 339 (1998), pp. 229-234
[15.]
H.E. Lebovitz.
Insulin secretagogues: old and new.
Diabetes Rev, 7 (1999), pp. 139-153
[16.]
R. Turner, C. Cull, R. Holman.
UK Prospective diabetes study 17: a nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non insulin-dependent diabetes mellitus.
Ann Intern Med, 124 (1996), pp. 136-145
[17.]
J. Rosenstock, E. Samols, D.B. Muchmore, J. Schneider, The Glymepiride Study Group.
Glymepiride, a new oncedaily suifonylurea: a double-blind placebo-controlled study of NIDDM patients.
Diabetes Care, 19 (1996), pp. 1194-1200
[18.]
K.E. Draeger, K. Wernicke-Panten, H.J. Lomp, E. Schuler, R. Rosskamp.
Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glymepiride (Amaryl): a double-blind comparison with glibenclamide.
Horm Metab Res, 28 (1996), pp. 419-425
[19.]
R.B. Goldberg, S.M. Holvey, A. Schnelder.
Dose-response study of glymepiride in patients with NIDDM who have previously received sulfonylurea agents.
Diabetes Care, 19 (1996), pp. 849-856
[20.]
G.E. Sonnenberg, D.C. Garg, D.J. Weidler, R.M. Dixon, L.A. Jaber, A.J. Bowen, et al.
Short-term comparison of once-versus twice-daily administration of glymepiride in patients with non insulin-dependent diabetes mellitus.
Ann Pharmacother, 31 (1997), pp. 671-676
[21.]
K. Cusi, R.A. De fronzo.
Metformin: a review of its metabolic effects.
Diabetes Rev, 6 (1998), pp. 89-131
[22.]
K. Johansen.
Efficacy of metformin in the treatment of NIDDM. Metaanalysis.
Diabetes Care, 22 (1999), pp. 33-37
[23.]
A.J. Garber, T.G. Duncan, A.M. Goodman, D.J. Mills, J.L. Rohif.
Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.
Am J Med, 102 (1997), pp. 491-497
[24.]
R. Defronzo, A. Goodman, et al.
Efficacy of metformin in patients with NIDDM.
N Engl J Med, 333 (1995), pp. 541-549
[25.]
P.W. Stacpoole.
Metformin and lactic acidosis. Guilt by association?.
Diabetes Care, 21 (1998), pp. 1587-1588
[26.]
M. Bayraktar, N. Adalar, D.H.A. Van Thiel.
comparison of acarbose versus metformin as an adjunt therapy in sulfonylurea-treated NIDDM patients.
Diabetes Care, 19 (1996), pp. 252-259
[27.]
A.J. Scheen.
Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
Diabetes Metabolism, 24 (1998), pp. 311-320
[28.]
R. Coniff, J.A. Shapiro, D. Robbins, R. Kleinfield, T. Seaton, P. Beisswenger, et al.
Reduction of glycosilated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dosecomparison study.
Diabetes Care, 18 (1995), pp. 817-824
[29.]
J. Hoffman, M. Spengler.
Efficacy of 24- week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients.
Diabetes Care, 17 (1994), pp. 561-566
[30.]
R.R. Holman, R.C. Turner, Cull CA, on behalf of the UKPDS Study Group.
A randomized double-blind trial of Acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44).
Diabetes Care, 22 (1999), pp. 960-964
[31.]
P. Segal, P.U. Felg, G. Scherntbaner, K.P. Ratzmann, J. Rybka, D. Petzinna, et al.
The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Diabetes Care, 20 (1997), pp. 687-691
[32.]
D.R. Owens.
Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drugs.
Diabet Med, 15 (1998), pp. 28-36
[33.]
T. Marbury, W.C. Huang, P. Strange, H. Lebovitz.
Repaglinide versus glyburide a one-year comparison trial.
Diabetes Res Clin Pract, 43 (1999), pp. 155-166
[34.]
Y. Iwamoto, Kosaka k, T. Kuzuya, Y. Akaa.
Effects of troglitazone. A new hipoglycernic agent in patients with NIDDM poorly controlled by diet.
Diabetes Care, 19 (1996), pp. 151-155
[35.]
G.L. Plosker, D. Faulds.
Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Drugs, 57 (1999), pp. 409-438
[36.]
P. Watkins, R. Whitcomb.
Hepatic dysfunction associated with troglitazone.
N Engl J Med, 338 (1998), pp. 916-917
[37.]
R.C. Turner, C.A. Cull, V. Frighi, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group.
Glycernic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49).
JAMA, 281 (1999), pp. 2005-2012
[38.]
L.S. Hermann, B. Schersten, P.O. Bitzen, T. Kjellstrom, F. Lindgarde, A. Melander.
Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations.
Diabetes Care, 17 (1994), pp. 1100-1109
[39.]
UK Prospective Diabetes Study 28.
A randomized trial of efficacy of early adition of metformin in sulfony. Lurea-treated type 2 diabetes.
Diabetes Care, 21 (1998), pp. 87-92
[40.]
D.S. Bell, M.S. Mayo.
Outcome of metformin- facilitated reinitiation of oral diabetic therapy in insulin-treated patients with.
Endocrine Practice, 3 (1997), pp. 73-76
[41.]
J. Olsson, G. Lindberg, M. Gottsater, K. Lindwall, A. Sjostrand, A. Tisell, et al.
Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study.
Diabetologia, 43 (2000), pp. 558-560
[42.]
J.L. Chiasson, R.G. Joss, J.A. Hunt, C. Palmason, N.W. Rodger, S.A. Ross, et al.
The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled trial.
Ann Intern Med, 121 (1994), pp. 928-935
[43.]
R. Coniff, J.A. Shapiro, T. Seaton, G. Bray.
Multicenter, placebo-controlled trial comparing acarbose with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
Am J Med, 98 (1995), pp. 443-451
[44.]
P.S. Johnston, J.V. Santiago, R.F. Coniff, Hoogwerf, F.X. Pi-Sunyer, A. Krol.
Effects of the carbohidrate inhibitor miglitol in the sulfonylurea-treated non-insulindependent diabetes mellitus patients.
Diabetes Care, 17 (1994), pp. 20-29
[45.]
J. Rosenstock, A. Brown, J. Fischer, A. Jain, T. Littlejohn, D. Nadeau, et al.
Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
Diabetes Care, 21 (1998), pp. 2050-2055
[46.]
R. Moses, R. Slobodniuk, S. Boyages, S. Colagiuri, W. Kidson, J. Carter, et al.
Effect of repaglinide addition to metformin monotherapy on glycernic control in patients with type 2 diabetes.
Diabetes Care, 22 (1999), pp. 119-124
[47.]
T.B. Kaye.
Triple oral antidiabetic therapy.
J Diabet Complications, 12 (1998), pp. 311-313
[48.]
E.S. Horton, F. Whitehouse, M.N. Ghazzi, T.C. Vennable, R.W. Whitcomb, The Troglitazone Study Group.
Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes.
Diabetes Care, 21 (1998), pp. 1462-1469
[49.]
Y. Iwamoto, K. Rosaka, T. Kuzvyat, Y. Akanuma, Y. Shigeta, T. Kaneko.
Effect of combination of troglitazone and sulfonylureas in patients with type 2 diabetes who where poorly controlled by sulphonylurea therapy alone.
Dlabet Med, 13 (1996), pp. 365-370
[50.]
S.E. Inzucchi, D.G. Maggs, G.R. Spollett, S.L. Page, F.S. Rife, V. Walton, et al.
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
N Engl J Med, 338 (1998), pp. 867-872
[51.]
A.L. Peters, M.B. Davidson.
Insulin plus sulphonylurea agent for treating type 2 diabetes.
Ann Intern Med, 115 (1991), pp. 45-53
[52.]
J.L. Johnson, S.L. Wolf, U.M. Kabadi.
Efficacy of insulin and sulphonylurea combination therapy in type 2 diabetes. A Meta-analysis of the Randomized Placebo-Controlled Trials.
Arch Intern Med, 156 (1996), pp. 259-264
[53.]
H. Yki-Jarvinen, M. Kauppila, E. Kjansuu, J. Lahti, T. Marjanen, et al.
Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus.
N Engl J Med, 327 (1992), pp. 1426-1433
[54.]
H. Yki-Jarvinen, L. Ryysy, M. Kauppila, E. Kujansuu, J. Lahti, T. Marjanen, et al.
Effect of obesity on the response to insulin therapy in non-insulin-dependent diabetes mellitus.
J Clin Endocrinol Metab, 82 (1997), pp. 4037-4043
[55.]
M.C. Riddle, J. Schneider, Glymepiride Combination Group.
Begining insulin treatment of obese patients with evening 70/30 insulin plus glymepiride versus insulin alone..
Diabetes Care, 21 (1998), pp. 1052-1057
[56.]
C. Abraira, W.G. Henderson, J.A. Colwell, F.Q. Nuttall, J.P. Comstock, N.V. Emanuelle, et al.
Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycernic control and complications (VA CSDM).
Diabetes Care, 21 (1998), pp. 574-579
[57.]
K. Osei, T.M. O’Dorislo, J.M. Falko.
Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism.
Am J Med, 77 (1984), pp. 1002-1009
[58.]
M.C. Riddle, J.S. Hart, D.J. Bouma, B.E. Phillipson, G. Youker.
Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects.
Diabetes Care, 12 (1989), pp. 623-629
[59.]
V. Trischitta, S. Ita1ia, M. Raimondo, V. Guardabasso, C. Licciardello, F. Runello, et al.
Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. It is predictable?.
J Endocrinol Invest, 21 (1998), pp. 744-747
[60.]
M. Riddle, J. Hart, P. Bingham, C. Garrison, P. McDaniel.
Combined therapy for obese type 2 diabetes; suppertime mixed insulin with daytime sulfonylurea.
Am J Med Sci, 303 (1992), pp. 151-156
[61.]
D.S. Schade, W.J. Mitchell, G. Griego.
Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinica1 tria1.
JAMA, 257 (1987), pp. 2441-2445
[62.]
L. Landstedt-Hallin, U. Adamson, P. Arner, J. Bolinder, P.E. Lins.
Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.
Diabetes Care, 18 (1995), pp. 1183-1186
[63.]
M.L. Shank, S. Del Prato, R.A. DeFronzo.
Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM.
Diabetes, 44 (1995), pp. 165-172
[64.]
M.N. Feinglos, C.R. Thacker, B. Lobaugh, D.D. DeAtkine, D.B. McNeil, et al.
Combination insulin and sulphonylurea therapy in insulin-requiring type 2 diabetes mellitus.
Diab Res Clin Pract, 39 (1998), pp. 193-199
[65.]
C.C. Chow, L.W. Tsang, J.P. Sorensen, C.S. Cockarm.
Comparison of insulin with or without continuation of oral hypoglycemicx agents in the treatment of secondary failure in NIDDM patients.
Diabetes Care, 18 (1995), pp. 307-314
[67.]
D. Giugliano, A. Quatraro, G. Consoli, A. Minei, A. Ceriello, et al.
Metformion for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.
Eur J Clin Pharmacol, 44 (1993), pp. 107-112
[68.]
H. Yki-Jarvinen, L. Ryysy, K. Nikkila, T. Tolukas, R. Vanamo, M. Heikkila.
Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial.
Ann Intern Med, 130 (1999), pp. 389-396
[69.]
S. Makimattila, K. Nikkila, H. Yki-Jarvinen.
Causes of weight gain during insulin therapy with and without metformin in patients with type 2 diabetes mellitus.
Diabetologia, 42 (1999), pp. 406-412
[70.]
L. Avilés-Santa, J. Sinding, P. Raskin.
Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med, 131 (1999), pp. 182-188
[71.]
F. Relimpio, A. Pumar, F. Losada, M.A. Mangas, D. Acosta, R. Astorga.
Adding metformin versus insulin dose increase in insulin-treated bud poorly controlled type 2 diabetes mellitus. An open-label randomized trial.
Diabetic Med, 15 (1998), pp. 997-1002
[73.]
D.E. Kelley, P. Bidot, Z. Freedman, B. Haag, D. Podlecki, et al.
Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
Diabetes Care, 21 (1998), pp. 2056-2061
[74.]
R.F. Coniff, J.A. Shapiro, T.B. Seaton, B.J. Hoogwerf, J.A. Hunt.
A double-blind placebo-controlled tria1 evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes.
Diabetes Care, 18 (1995), pp. 928-932
[75.]
R.R. Holman, C.A. Cull, R.C. Turner.
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44).
Diabetes Care, 22 (1999), pp. 960-964
[76.]
A. Mitrakou, N. Tountas, A.E. Raptis, R.J. Bauer, H. Schulz, S.A. Raptis.
Longterm effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Diabetic Med, 15 (1998), pp. 657-660
[78.]
S. Schwartz, P. Raskin, V. Fonseca, J.F. Graveline, Troglitazone and Exogenous Insulin Study Group.
Effect of troglitazone in insulintreated patients with type 2 diabetes.
N Engl J Med, 338 (1998), pp. 861-866
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
